1Y Close · As of Aug 26, 2026
HEM Pharma operates in the Professional Services sector.
Legal name: HEM Pharma Inc.
In fiscal year 2025, HEM Pharma (376270) reported revenue of 13.0 billion KRW, down 13.9% from 15.1 billion KRW a year earlier.
Operating profit was -15.6 billion KRW and net income was -23.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 289.1 billion KRW, with a P/B of 55.44.
These figures can be verified in the DART filing (receipt no. 20260729000467).
Recent Filings
Semi-Annual Report (2026.06)
Officer/Major Shareholder Ownership Report
Large Shareholding Report (General)
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | Semi-Annual Report (2026.06) |
| 2026-08-20 | Officer/Major Shareholder Ownership Report |
| 2026-08-20 | Large Shareholding Report (General) |
| 2026-08-19 | Corporate Briefing (IR) |
| 2026-08-14 | Securities Issuance Result (Voluntary Disclosure) |